Vironova AB - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 19 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Vironova AB - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Vironova AB - Product Pipeline Review - 2014', provides an overview of the Vironova AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vironova AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Vironova AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Vironova AB's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Vironova AB's pipeline products

Reasons to buy

- Evaluate Vironova AB's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Vironova AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Vironova AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Vironova AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vironova AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Vironova AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Vironova AB Snapshot 4
Vironova AB Overview 4
Key Information 4
Key Facts 4
Vironova AB - Research and Development Overview 5
Key Therapeutic Areas 5
Vironova AB - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Vironova AB - Pipeline Products Glance 9
Vironova AB - Early Stage Pipeline Products 9
Discovery Products/Combination Treatment Modalities 9
Vironova AB - Drug Profiles 10
Drug to Inhibit Capsid Protein for HIV-1 Infection 10
Product Description 10
Mechanism of Action 10
R&D Progress 10
Small Molecule for Influenza A Infections 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
VN-180 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Vironova AB - Pipeline Analysis 13
Vironova AB - Pipeline Products by Target 13
Vironova AB - Pipeline Products by Molecule Type 14
Vironova AB - Pipeline Products by Mechanism of Action 15
Vironova AB - Recent Pipeline Updates 16
Vironova AB - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
Coverage 18
Secondary Research 18
Primary Research 18
Expert Panel Validation 18
Contact Us 19
Disclaimer 19

List of Tables
Vironova AB, Key Information 4
Vironova AB, Key Facts 4
Vironova AB - Pipeline by Indication, 2014 6
Vironova AB - Pipeline by Stage of Development, 2014 7
Vironova AB - Monotherapy Products in Pipeline, 2014 8
Vironova AB - Discovery, 2014 9
Vironova AB - Pipeline by Target, 2014 13
Vironova AB - Pipeline by Molecule Type, 2014 14
Vironova AB - Pipeline Products by Mechanism of Action, 2014 15
Vironova AB - Recent Pipeline Updates, 2014 16
Vironova AB, Subsidiaries 17